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Startle diseaseDefects in glycinergic synaptic transmission in humans, cattle, and rodents result in an exaggerated startle
reﬂex and hypertonia in response to either acoustic or tactile stimuli. Molecular genetic studies have
determined that mutations in the genes encoding the postsynaptic glycine receptor (GlyR) α1 and β subunits
(GLRA1 and GLRB) and the presynaptic glycine transporter GlyT2 (SLC6A5) are the major cause of these
disorders. Here, we report the ﬁrst genetically conﬁrmed canine cases of startle disease. A litter of seven Irish
wolfhounds was identiﬁed in which two puppies developed muscle stiffness and tremor in response to
handling. Although sequencing of GLRA1 and GLRB did not reveal any pathogenic mutations, analysis of SLC6A5
revealed a homozygous 4.2 kbmicrodeletion encompassing exons 2 and 3 in both affected animals. This results
in the loss of part of the large cytoplasmic N-terminus and all subsequent transmembrane domains due to a
frameshift. This genetic lesion was conﬁrmed by deﬁning the deletion breakpoint, Southern blotting, and
multiplex ligation-dependent probe ampliﬁcation (MLPA). This analysis enabled the development of a rapid
genotyping test that revealed heterozygosity for the deletion in the dam and sire and three other siblings,
conﬁrming recessive inheritance. Wider testing of related animals has identiﬁed a total of 13 carriers of the
SLC6A5 deletion as well as non-carrier animals. These ﬁndings will inform future breeding strategies and
enable a rational pharmacotherapy of this new canine disorder.ology, University of California,
34 0391.
Pharmacology, The School of
, UK. Fax: +44 207 753 5902.
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Hyperekplexia or startle disease affects newborn children and
is characterized by noise- or touch-induced non-epileptic seizures
that result in muscle stiffness and apnea (suspension of breathing).
Although a rare orphan disease (deﬁned as b200,000 affected
individuals worldwide), this disorder can have serious consequences,
including brain damage and/or sudden infant death (Harvey et al.,
2008). The primary cause of startle disease is defective inhibitory
glycinergic transmission due to missense, nonsense, or frameshift
mutations in the glycine receptor (GlyR) α1 gene (GLRA1) (Shiang
et al., 1993, 1995; Chung et al., 2010), although large deletions ofexons 1–7 have also been reported (Brune et al., 1996; Becker et al.,
2006). Mutations are also found in the genes encoding the GlyR β
subunit gene (GLRB; Rees et al., 2002) and the presynaptic glycine
transporter GlyT2 (SLC6A5) (Rees et al., 2006; Eulenburg et al., 2006).
Animal disorders similar to startle disease/hyperekplexia have been
reported in cattle (Harper et al., 1986; Gundlach, 1990; Gundlach
et al., 1988; Lummis et al., 1990; Pierce et al., 2001; Charlier et al.,
2008; Gill et al., 2011), horses (Gundlach et al., 1993), and dogs
(Fox et al., 1984), but only in certain cases has the underlying genetic
lesion been deﬁnitively identiﬁed (Table 1). For example, a nonsense
mutation (c.C156A, p.Y24X) in exon 2 of GLRA1 causes inherited
congenital myoclonus (ICM) in Poll Hereford calves (Pierce et al.,
2001), while a missense mutation (c.T809C, p.L270P) in exon 4 of
SLC6A5 causes congenital muscular dystonia 2 (CMD2) in Belgian Blue
cattle (Charlier et al., 2008;Gill et al., 2011). The identiﬁcationof common
causal genes links these animal disorders to human startle disease/
hyperekplexia. Two other related disorders—inherited myoclonus in
Peruvian Paso horses (Gundlach et al., 1993) and familial reﬂex
myoclonus in Labrador retrievers (Fox et al., 1984)—are reminiscent of
deﬁcits in glycinergic transmission, although investigations into the
Table 1
Startle disorders in livestock and companion animals.
Inherited congenital myoclonus (ICM) in Poll Hereford cattle
Genetics: Autosomal recessive inheritance. Nonsense mutation (c.C156A, p.Y24X) in exon 2 of GLRA1, encoding the glycine receptor α1 subunit, resulting in a lack of synaptic
α1β GlyRs. Clinical signs: Hyperesthesia (increased sensitivity to stimuli) and muscle rigidity, tremor, and myoclonic jerks of the skeletal musculature which occur
spontaneously and in response to tactile, visual, or auditory stimuli. Survival of calves with ICM for up to ten days has been reported, but key independent activities required
for survival, such as standing and feeding, are impaired. There are no detectable pathological lesions in the central nervous system, although compensatory mechanisms have
been detected in affected animals including increases in presynaptic glycine uptake and GABAergic transmission. References: Harper et al., 1986; Gundlach, 1990; Gundlach
et al., 1988; Lummis et al., 1990; Pierce et al., 2001.
Congenital muscular dystonia type 2 (CMD2) in Belgian Blue cattle
Genetics: Autosomal recessive inheritance. Missense mutation (c.C156A, p.Y24X; c.T809C, p.L270P) in exon 4 of SLC6A5, encoding the neuronal glycine transporter GlyT2,
resulting in a loss of presynaptic glycine uptake and release. Clinical signs: Extreme muscle stiffness and tremor following acoustic, tactile, or visual stimulation. No overt
pathological defects in the central nervous system. CMD2 homozygotes die within 24–48 h after birth due to respiratory difﬁculties. References: Charlier et al., 2008; Gill et al.,
2011.
Inherited myoclonus in Peruvian Paso horses
Genetics: Likely autosomal recessive inheritance. Genetic lesion unknown, although likely to be amutation in GLRA1, since [
3
H]strychnine binding sites are lost in the spinal cord
ventral horn but retained in the dorsal horn, suggesting a loss ofα1β but notα3βGlyRs. Clinical signs: From birth, myoclonic contractions of the skeletal musculature resulting
from tactile or auditory stimuli. Additional evidence of hip pain, a characteristic “bunny hopping” gait with the hind limbs. If placed upright, animals are able to walk and run
but in some cases are unable to rise alone. Reference: Gundlach et al., 1993.
Familial reﬂex myoclonus in Labrador retriever dogs
Genetics: Likely autosomal recessive inheritance. Genetic lesion unknown. Clinical signs: At six weeks old, three Labrador retrievers presented with muscle rigidity triggered by
voluntary movements or handling, and respiratory distress was observed in severe episodes. Electromyogram analysis revealed increased motor unit amplitude with
polyphasic action potentials without myotonic discharges. Normal serum chemistry, urinalysis, and muscle biopsies. Reference: Fox et al., 1984.
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samples from affected animals. These startle disorders should be
distinguished from exercise-induced muscle hypertonicity disorders,
such as episodic falling in Cavalier King Charles spaniels (Herrtage and
Palmer, 1983).
Here, we report the discovery of startle disease in Irish wolfhounds
from the United States and identify the causative mutation—a
microdeletion in the gene encoding the presynaptic glycine trans-
porter GlyT2. We also demonstrate how rapid genotyping tests can be
used to conﬁrm diagnosis, identify carriers, and guide future breeding
strategy, thus avoiding further animal distress and premature death.
Methods
Histopathology and histochemistry
A full necropsy was performed on both affected puppies following
humane euthanasia. Tissues including brain and spinal cord were
processed into parafﬁn by standard procedures. In addition, specimens
from the biceps femoris, vastus lateralis, and triceps brachii muscles
were collected and frozen in isopentane pre-cooled in liquid nitrogen.
Cryosections were cut (8 μm) and the following histochemical stains
and reactions were performed: hematoxylin and eosin, modiﬁed
Gomori trichrome, periodic acid Schiff, phosphorylase, esterase, ATPase
reactions at pH of 9.8 and 4.3, nicotinamide adenine dinucleotide-
tetrazolium reductase, succinic dehydrogenase, acid phosphatase,
alkaline phosphatase, and oil red O (Dubowitz and Sewry, 2007).
PCR and DNA sequencing
PCR was performed using 50 ng genomic DNA as template and
AccuPrime Pfx SuperMix with exon-speciﬁc primers for GLRA1, GLRB,
and SLC6A5 (Table S1). PCR conditions were 35 cycles of 94 °C for
1 min, 60 °C for 1 min, and 68 °C for 2 min. PCR products were gel
puriﬁed using a QIAQuick Gel Extraction Kit (QIAGEN) for Sanger DNA
sequencing byDNA Sequencing and Services (MRC-PPU, College of Life
Sciences, University of Dundee, Scotland; www.dnaseq.co.uk) using
Applied Biosystems Big-Dye version 3.1 chemistry on an ABI 3730
automated capillary DNA sequencer. DNA sequences were analyzed
using Sequencher (Gene Codes Corporation, Ann Arbor, USA).Southern blotting
Genomic DNA (2.5 μg) was digested with HindIII, separated on a
1% (wt./vol.) agarose gel and subjected to Southern blotting onto
Hybond-N membrane (GE Healthcare, Little Chalfont, UK). The blot
was probed using a SLC6A5 exon 1 PCR amplicon radiolabeled using
α[
32
P]dCTP and the Prime-It II Random Primer Labeling Kit (Agilent,
Wokingham, UK). Hybridization was at 65 °C overnight in a buffer
containing 6× SSC, 10% (wt./vol.) Dextran sulphate, 1% (wt./vol.) SDS,
5× Denhardt's Solution, and 100 μg/ml denatured herring spermDNA.
Final washes of the blot were at 0.1× SSC, 0.1% SDS at 65 °C for 30 min.
Hybridizing fragments were revealed by exposure to X-ray ﬁlm for
14 days.
Multiplex ligation-dependent probe ampliﬁcation (MLPA) analysis
We designed ﬁve MLPA probe pairs corresponding to the ﬁrst ﬁve
coding exons of the canine GlyT2 gene (SLC6A5; NC_006603 on
chromosome 21; Table S2). Probes for exon 2 were positioned just
inside intron 2, due to the high GC content (78%) of this exon. Criteria
for MLPA probe design were as previously described (Schouten et al.,
2002). Control probe pairs were designed to recognize an unrelated
gene (CFTR: NC_006596) on chromosome 14. Probes generated
ampliﬁcation products ranging in size from 87 to 113 bp and had an
annealing temperature higher than 70 °C as recommended in RAW
Probe software (MRC-Holland, Amsterdam, The Netherlands) using
standard MLPA conditions (Schouten et al., 2002). PCR products were
analyzed on an ABI 3130xl capillary electrophoresis apparatus
(Applied Biosystems, Lennik, Belgium). Normalization of SLC6A5
speciﬁc probe signals was performed by dividing the values obtained
by the combined signal of the control probes.
Results
Startle disease in Irish wolfhounds
Two Irish wolfhound puppies, onemale and one female, were born
with clinical signs similar to human hyperekplexia and other
glycinergic disorders observed in cattle (Fig. 1A, Table 1, and Video
S1 online). The puppies, whose ﬁve siblings all appeared normal,
developed extensor rigidity and tremor beginning 5–7 days post-
Fig. 1. PCR assays reveal that a SLC6A5 microdeletion is associated with startle disease in Irish wolfhounds. (A) Photograph of one of two affected puppies demonstrating lateral
recumbency and an extended posture (see Video S1 online). (B) PCR panels for SLC6A5 exon 2 (754 bp), exon 3 (513 bp), and a large genomic fragment encompassing exons 1–4
(target size, 8.2 kb). Note that exon 2 and exon 3 fragments fail to amplify from the affected dogs (samples and 1 and 2,−/−) but can be robustly ampliﬁed using genomic DNA from
the dam and ﬁve other siblings. Although the 8.2 kb exon 1–4 fragment was not ampliﬁed from wild-type animals or carriers (due to the large size and GC-rich nature of the
amplicon), a 4 kb PCR product was observed in both affected dogs (−/−), the dam, and three of the littermates (sibs 1, 4, and 5—all likely to have a+/− genotype). (C) Since exons 1
and 4–16 were ampliﬁed from affected animals, these results strongly suggest that a microdeletion encompassing SLC6A5 exons 2 and 3 is the genetic cause of this startle disorder,
with the two remaining animals (sibs 2 and 3) being homozygous for the wild-type allele (+/+).
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were relaxed or sleeping. The puppies were unable to stand and
showed a typical rigid extended posture in all four limbs. Cyanosis
was notedwhile the dogswere suckling or during tube feeding. Due to
the progression of clinical signs, feeding difﬁculty, and development
of lung congestion, the dogs were humanely euthanized at approx-
imately 11 weeks of age and full necropsies were performed.
Histopathology and histochemistry
Both puppies were small for their age with weights of 1446 and
1559 g, while the normal littermates (n=5) averaged 2642 g, ranging
from 2495 to 2778 g. The primary abnormality on gross examination
of both animals was consolidated (neither ﬂoated in formalin) and
hemorrhagic lungs, with the male puppy more severely affected than
the female. The esophagus in eachof the puppieswasnoticeably dilated,
more so in the female than the male. No macroscopic abnormalities
of the brain and spinal cord were noted. At the light microscopic
level, moderate interstitial pneumonia was noted in both puppies. No
signiﬁcant pathological abnormalities were noted in the brain or
spinal cord of either animal. All muscles appeared to have developed
normally with myoﬁber size appropriate for the age of the puppies
and a normal mosaic pattern of muscle ﬁber types. Intramuscular
nerve branches were normal in appearance. There was no evidence of
a primary muscle or nerve disease in any of the muscle specimens.
Candidate gene analysis—GLRA1, GLRB, and SLC6A5
Given the similarity of clinical signs to startle disease, primers
were designed to amplify exons and ﬂanking splice donor, acceptor,
and branch-point sites for the major causative genes, GLRA1, GLRB,
and SLC6A5, deriving gene structures in silico using the UCSC Genome
Browser (http://genome.ucsc.edu/). PCR ampliﬁcation (for primers,
see Table S1) using proofreading Pfx DNA polymerase and directsequencing revealed surprisingly few exonic variants in GLRA1 and
GLRB. No SNPs were detected in GLRA1, and only two homozygous
SNPs were detected in GLRB: T1380A (p.P438P, dbSNP: rs22406580)
and c.G1226A causing a p.C385Y substitution in the mature GlyR β
subunit M3–M4 intracellular loop. However, both these variants were
also found in unaffected littermates, ruling out a pathogenic role.
Variation was also absent from exons 1 and 4–16 of the SLC6A5 gene.
However, we consistently failed to amplify SLC6A5 exons 2 and 3 with
several different primer sets from genomic DNA isolated from the two
affected dogs. Since control experiments revealed that these primer
sets were functional in PCRs using template DNAs from the unaffected
littermates and dam (Fig. 1), we suspected that a microdeletion
encompassing exons 2 and 3 could explain this anomaly. To
investigate this possibility, we used long-distance PCR to amplify
the genomic region encompassing SLC6A5 exons 1–4 generating a
fragment predicted to be 8.2 kb in size. Although we failed to amplify
this fragment from control DNAs (presumably due to the highly GC-
rich exon 2) in the two affected dogs, the unaffected dam, and three
of the unaffected littermates, we observed robust PCR products
migrating at 4 kb, while the two remaining unaffected littermates had
no PCR products in this size range. These results suggested that the
two affected dogs were homozygous for a microdeletion of 4.2 kb,
while the dam and littermates 1, 4, and 5 were heterozygous for this
deletion. Littermates 2 and 3 would be predicted to be homozygous
wild-type due to the absence of the 4 kb deletion fragment.
Mapping the SLC6A5 deletion breakpoint
In order to conﬁrm this deletion and determine the exact
breakpoint in the deleted allele, we cloned and sequenced the 4 kb
deletion fragment. This analysis revealed that the deletion spanned
both exons 2 and 3, starting 32 bp upstream of exon 2 and ending
504 bp downstream of the end of exon 3 (Figs. 1 and 2). The presence
of a dinucleotide (gt) repeat at the breakpoint is relevant since
Fig. 2. Sequencing of the SLC6A5 exon 1–4 amplicon reveals a microdeletion encompassing exons 2 and 3. (A) DNA sequence of the SLC6A5 deletion fragment from affected animals
and the dam revealed a 4230 bpmicrodeletion, resulting in the loss of exons 2 and 3 encoding the GlyT2 N-terminus. (B) Breakpoint sequence with the position of the microdeletion
indicated by an arrow. Note that the deletion is positioned just downstream of a dinucleotide (gt) repeat, and while the dog genome consensus sequence contains 11 copies of this
dinucleotide repeat, all Irish wolfhounds genotyped in this study (wild-type, heterozygous, and mutant) had 14 copies of this repeat.
187J.L. Gill et al. / Neurobiology of Disease 43 (2011) 184–189a common cause of microdeletions is slipped mispairing of direct
repeat sequences in close proximity to one another. This can occur
during DNA replication when the primer and template strands can
transiently dissociate and reassociate in a misaligned conﬁguration. If
the primer strand which contains the newly synthesized ﬁrst direct
repeat dissociates from the template strand and misaligns by slippingFig. 3. Combined pedigree analysis and genotyping reveals additional SLC6A5 microdel
microdeletion amplicons (see Fig. 1) allowed the identiﬁcation of a total of 13 heterozygous c
offer rapid diagnostic genotyping for the large litter from dam 4 and sire 4, allowing the owne
(+/−) from normal (+/+) animals, this disorder can effectively be eliminated from breed
unexpectedly, suggesting that dam 5 may also be a carrier of the SLC6A5 microdeletion. Fo
rather than categorically proven.forward at the second direct repeat, then continued DNA synthesis
will result in the deletion of one of the direct repeats as well as the
intervening sequence (Ball et al., 2005). Additional pedigree analysis
and genotyping of DNA samples from related animals (Fig. 3) revealed
a total of 13 carriers of the GlyT2 microdeletion—including the sire
of the affected dogs—and two other likely carriers. Although DNAetion carriers. Pedigree analysis combined with PCR genotyping of exon 2, 3, and
arriers and 2 additional suspected carriers (dam 1 and dam 5). Notably, we were able to
r tomanage future breeding strategy. By distinguishing phenotypically identical carriers
ing stock in a single generation. It is also noteworthy that three offspring of sire 5 died
r genotypes in brackets, DNA samples were not available and genotypes are suggested
188 J.L. Gill et al. / Neurobiology of Disease 43 (2011) 184–189samples were not available for all animals in the pedigree, this
provided a possible explanation for the unexplained deaths of three
animals in another litter, where we conﬁrmed that the sire was a
carrier of the SLC6A5 lesion (Fig. 3).
The deletion of exons 2 and 3 results in the loss of part of the large
cytoplasmic N-terminus, thought to be involved in the trafﬁcking of
GlyT2 to synaptic sites, and a loss of all subsequent transmembrane
domains via a frameshift. We also conﬁrmed the presence of the
microdeletion using two additional methods—Southern blotting
(Southern, 2006) using a probe derived from exon 1 and multiplex
ligation-dependent probe ampliﬁcation (MLPA; Schouten et al., 2002)
using probe sequences in exons 1, 3, 4, and 5, and intron 2 (Table S2).
Both methods conﬁrmed the loss of exons 2 and 3 in heterozygotes
and homozygous affected animals (Fig. 4).Discussion
This study describes the clinical signs and pathological changes
associated with a new canine disorder: startle disease in Irish
wolfhounds. In addition, we report the underlying genetic cause—a
microdeletion in the GlyT2 gene SLC6A5. Consistent with previous
reports of GlyT2mutations in human hyperekplexia (Rees et al., 2006;
Eulenburg et al., 2006) and bovine congenital muscular dystonia type
2 (Charlier et al., 2008; Gill et al., 2011), this canine disorder exhibited
an autosomal recessive mode of inheritance, consistent with a loss
of function of GlyT2. However, it is noteworthy that this study
represents the ﬁrst report of a SLC6A5 microdeletion in any species,
suggesting that copy number variations in the GlyT2 gene should be
considered a risk factor for startle disorders.Fig. 4. Conﬁrmation of the SLC6A5 deletion using Southern blotting and multiplex ligation
HindIII and probed with the exon 1 PCR amplicon is predicted to reveal a 6672 bp fragment in
observed sizes and banding patterns of DNA fragments hybridizing with the exon 1 probe a
homozygous affected (−/−) animals. (B, C) MLPA analysis also reveals robust detection of c
for probes in intron 2 (just downstream of the GC rich exon 2) and exon 3 were reduced by 3
consistent with a loss of probe binding sites in genomic DNA.The clinical phenotype produced as a result of the microdeletion
identiﬁed in the affected wolfhounds most likely results from a loss of
synaptic glycine since the major role of GlyT2 is to maintain a high
presynaptic pool of glycine for inhibitory neurotransmission (Gomeza
et al., 2003; Rousseau et al., 2008). In GlyT2 knockoutmice, this results
in the development of an acutemotor disorder in the second postnatal
week, characterized by rigidity, tremor, and an impaired righting
reﬂex that is followed shortly after by death (Gomeza et al., 2003).
Similarly, cattle with CMD2 caused by a missense mutation (p.L270P)
in the GlyT2 gene suffer severe episodes of muscle rigidity and tremor
upon acoustic or tactile stimulation and usually die shortly after birth
due to respiratory difﬁculties (Charlier et al., 2008; Gill et al., 2011).
This early neonatal lethality might be explained by the fact that
defective presynaptic glycine uptake is predicted to affect the function
of all GlyR subtypes. In particular, GlyRs containing the α3 subunit
have recently been shown to play a role in rhythmic breathing
(Manzke et al., 2010) which may explain the breathing difﬁculties
seen in mice, cattle, and dogs with inactivating SLC6A5 mutations.
Given the cyanosis that developed during feeding and the pneumonia
observed in both animals whichmay have been caused or exacerbated
by compromised lung clearance, both puppies would have likely
died if they had not been humanely euthanized. However, no obvious
lesions in the brain, spinal cord, and muscle were observed, suggesting
that pharmacotherapy might have been effective. In this regard, it is
noteworthy that humanswithmutations in the GlyT2 gene also present
with neonatal touch and noise induced muscle stiffness and apnea
episodes (Rees et al., 2006; Eulenburg et al., 2006). These symptoms
respond to therapy with the benzodiazepine clonazepam, which
potentiates inhibitory GABAergic transmission and often improve in
theﬁrst yearof life (Rees et al., 2006; Eulenburg et al., 2006;Bakker et al.,-dependent probe ampliﬁcation. (A) Southern blotting of genomic DNA digested with
wild-type animals and a 2242 bp fragment in animals harboring the microdeletion. The
re in good agreement with these values in wild-type (+/+), heterozygous (+/−), and
ontrol probes (CFTRa and CFTRb), probes for SLC6A5 exons 1, 4, and 5. However, signals
5%–60% in heterozygous (+/−) animals and abolished in homozygous animals (−/−)
189J.L. Gill et al. / Neurobiology of Disease 43 (2011) 184–1892009). These differences suggest not only that compensatory mecha-
nismsmay exist in humans that do not operate in other species but also
that early intervention with clonazepam could treat the clinical signs
and improve survival rates in startle disease in animals.
In conclusion, we have identiﬁed a novel canine startle disorder with
an autosomal recessive mode of inheritance, which is caused by the
deletion of two coding exons from the GlyT2 gene, SLC6A5. The
identiﬁcation of the breakpoint and subsequent development of
diagnostic PCRs has allowed the development of a diagnostic test
(available via Laboklin http://www.laboklin.co.uk/). This has already
enabled Irish wolfhound breeders to identify heterozygous animals
(which have no discernable phenotypic differences when compared to
wild-type animals), enabling rational breeding programs to be imple-
mented that will limit further animal distress and premature death. This
also highlights the growing compendium of animal models of startle
disease that inform our knowledge of mechanisms of inhibitory
neurotransmission as well as startle disease/hyperekplexia.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.nbd.2011.03.010.
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